Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T
cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Immune evasion contributes to cancer growth and progression. Cancer cells have the ability
to activate different immune checkpoint pathways that harbor immunosuppressive functions …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Naïve CD8+ T cells can differentiate into effector (Teff), memory (Tmem) or exhausted (Tex)
T cells. These developmental pathways are associated with distinct transcriptional and …